CGBio, a South Korean regenerative medicine company, has officially launched its calcium hydroxylapatite (CaHA)-based collagen booster Facetem in Thailand through a strategic partnership with Berli Jucker Public Company Limited (BJC), a leading Thai distribution and healthcare firm. The launch marks a key step for the global No. 2 CaHA brand as it expands into Southeast Asia’s mature medical aesthetics market, leveraging BJC’s extensive network including Big C retail chain and healthcare channels.
Launch event and training program
The launch event featured a two-day program: a Train-the-Trainer hands-on session on day one, followed by an official symposium titled “Facetem Beyond Dual – The Lattice Pore Structural Regeneration” on day two. The training session attracted key opinion leaders and fellows from Siriraj Medical School, who evaluated Facetem’s injection feel, handling, and product distribution characteristics. Participants showed strong interest in the product’s uniform particle structure, which provides smooth injection, predictable outcomes, and natural tissue response compared to competitors.
Academic and clinical highlights
During the symposium, Prof. Dr. Rungsima, a leading Thai KOL, presented on CaHA’s evolution from a simple filler to a regenerative biostimulator that induces collagen and elastin production. She highlighted Facetem’s structural properties and growth potential in the Asia-Pacific region, as well as expanding body indications such as neck, hands, and abdomen. Dr. Carmelo Crisafulli from Dubai shared clinical experience using Facetem for skin tightening and remodeling across facial and body applications. Dr. Kiwoong Hong, a global KOL and developer of the CAST CODE protocol, introduced a CaHA-based treatment framework categorizing procedures into lifting (LL), structural contouring (SC), and skin regeneration (SR).
Market signal
Thailand is recognized as one of the most mature medical aesthetics markets in Southeast Asia, with clinicians placing high importance on safety, product characteristics, and academic evidence. The regenerative aesthetics segment—focusing on tissue regeneration and skin improvement beyond volume enhancement—is growing rapidly. CGBio’s partnership with BJC positions Facetem to capture this demand through academic marketing and clinical data expansion.
What buyers should watch
For overseas distributors and clinic buyers, Facetem’s global No. 2 CaHA market share and presence in over 32 countries signal a competitive product with established clinical backing. The partnership with BJC provides a strong local distribution and retail network in Thailand, which could serve as a gateway for broader Southeast Asian expansion. Buyers should monitor CGBio’s ongoing clinical data generation and academic activities in Thailand, as these will support product adoption in other regional markets.
Sourcing context
CGBio markets Facetem globally under the same brand name, while in South Korea and Indonesia it is sold as DCLASSY CaHA. The company’s focus on regenerative aesthetics and biostimulator technology aligns with current industry trends toward non-surgical skin remodeling and collagen induction. Importers and distributors seeking to add a CaHA-based product to their portfolio may find Facetem’s clinical differentiation and market traction relevant for evaluation.
Source: Read the original report | Published: June 09, 2026